Please login to the form below
Evotec
This page shows the latest Evotec news and features for those working in and with pharma, biotech and healthcare.
Bayer bulks up in women’s health again with non-hormonal contraceptive deal
It remains firmly committed to women’s health however, and just last week added to its pipeline in this area by signing a five-year research alliance with Evotec focusing on ... The Evotec and Daré deals sandwiched two other agreements signed in the
Latest news
-
Bayer extends alliance with Evotec in women’s health
There has been little progress in how these and other related conditions are diagnosed and treated, according to Evotec. ... Bayer and Evotec will both contribute drug targets to the alliance as well as other technology platforms, and will jointly
-
Evotec and Vifor announce joint venture for kidney disease treatments
in nephrology clinical development and commercialisation,” said Cord Dohrmann, chief scientific officer at Evotec. ... The discovery of novel nephrology therapeutics will be aided by analysis of clinical data provided by Evotec from the UK kidney
-
Evotec spins off cancer tech into new Breakpoint company
Will challenge AstraZeneca and others in DNA damage response. German biotech Evotec has decided to bundle its cancer therapeutic programmes focused on DNA damage response (DDR) into a new spin-off ... virtual” spin out that will still have access to
-
Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity
This deal extends Exscientia’s list of partnerships with pharma and biotech companies, with existing collaborations involving Roche, GSK, Sanofi and Evotec.
-
Galapagos expands presence in fibrosis, NASH with Evotec deal
Galapagos will have access to specific screening formats at Evotec to support the final pre-clinical development. ... We highly regard the scientific know-how of Evotec, and are hence very much looking forward to collaborating with the team.".
Bayer extends alliance with Evotec in women’s health
Evotec and Vifor announce joint venture for kidney disease treatments
Evotec spins off cancer tech into new Breakpoint company
Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity
Galapagos expands presence in fibrosis, NASH with Evotec deal
More from news
Approximately 16 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Alzheimer’s disease: the search for a cure
The companies, Abbvie, Astex Pharmaceuticals, Eisai, Johnson &Johnson, Lilly, MSD and Takeda, Evotec and Charles River, participate in research projects alongside academic scientists.
-
A snapshot of… Exscientia
We’ve also signed numerous major pharma collaborations with companies including Roche, Celgene, Sanofi, GSK and Evotec, estimated to be worth over $1bn in milestones and royalties.
-
Brain power: fresh approaches to Alzheimer’s drug discovery
Last month, Johnson &Johnson Innovation, Takeda and Evotec became the latest pharma research groups to join the initiative, alongside existing strategic partners AbbVie, Astex Pharmaceuticals, Eisai, Lilly and MSD. ... We’re excited to welcome Johnson
-
Pharma deals continue to slide
For example, Evotec, the German small molecule development company, is acquiring for $300m the US preclinical development company, Aptuit. ... 400. Aptuit (US). Evotec (DE). Company acquisition. Drug discovery and development to IND submission including
-
Deal Watch December 2016
320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for neurodegenerative diseases. ... upfront. And although the upfronts are a modest percentage of the headline figure, ranging from < 1% (BioInvent) to 15%
Alzheimer’s disease: the search for a cure
A snapshot of… Exscientia
Brain power: fresh approaches to Alzheimer’s drug discovery
Pharma deals continue to slide
More from intelligence
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Apitope strengthens its board with new director
He has also served on several boards including Ablynx, Evotec and Acambis.
-
Evotec CEO Werner Lanthaler temporarily stands down
Cites health reasons. Evotec's CEO Dr Werner Lanthaler, has temporarily stood down from his role within the company due to health reasons.
Apitope strengthens its board with new director
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Breaking the silence: It’s time to talk about the menopause
According to Werner Lanthaler, CEO of Evotec AG (a long-time partner of Bayer AG, well-known for their role in advocating for women’s health) in an interview with In
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
CEO, Head of Health, UK
-
Six figure salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Valneva COVID-19 vaccine more effective than AZ
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- US demand for COVID-19 antibody treatments rising fast
- Call for industry innovators to join working group
- Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19
- US COVID-19 booster programme expanded
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- Towards Better HCP Engagement – An Email Masterclass
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Valneva COVID-19 vaccine more effective than AZ
- Beyond yoga and smoothies – providing real support for employee well-being
- The Future of eHealth: Contactless Health Monitoring
- NICE looks internally for new chief executive
PMHub
Oxford PharmaGenesis
Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
